Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 3/20 | 0.41 |
| ▸ | CPT2 | P23786 | 2/20 | 0.41 |
| ▸ | WDR5 | P61964 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5116149 | 0.92 | SMN1; SMN2 (0.40) | TSHRMEN1ALDH1A1KMT2A | |
| Trifluoroacetic Acid SCHEMBL5117115 | 0.92 | KMT2A (0.43) | NPC1ALPLMEN1ALDH1A1KMT2A | |
| Trifluoroacetic Acid SCHEMBL5118147 | 0.92 | MCL1 (0.38) | TSHR | |
| Trifluoroacetic Acid SCHEMBL5108698 | 0.91 | WDR5 (0.40) | WDR5ALPLKMT2AMYCBRD4 | |
| Trifluoroacetic Acid SCHEMBL5110404 | 0.90 | GAA (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL5852443 | 0.88 | CTSD (0.41) | MEN1ALDH1A1KMT2ABRPF1TP53 | |
| Trifluoroacetic Acid SCHEMBL5117942 | 0.88 | METAP2 (0.40) | ALDH1A1KMT2ATP53 | |
| Trifluoroacetic Acid SCHEMBL5118117 | 0.86 | ACLY (0.39) | — | |
| Trifluoroacetic Acid SCHEMBL5112853 | 0.86 | CCR9 (0.38) | KMT2ATP53 | |
| Trifluoroacetic Acid SCHEMBL5116094 | 0.85 | F2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-21 | — | — | US | disclosed |
| US-7029654-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040106633-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6706021-B2 | ANTICOAGULANT FOR CATHETERS, DIALYSIS MACHINES, SYRINGES, TUBES, BLOOD LINES AND STENTS; TRYPSIN-LIKE SERINE PROTEASES SUCH AS THROMBIN; 3-BENZYLSULFONYLAMINO-6-METHYL-1-((2-GUANIDINOOXYETHYL) AMINOCARBONYLMETHYL)-2-PYRIDINONE | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030225115-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6566379-B1 | As proteolytic enzyme inhibitors; thrombin inhibitors; for therapy of pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema or inflammation in a mammal | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6472399-B2 | ANTICOAGULANTS; MAY BE EMBEDDED IN OR PHYSICALLY LINKED TO MATERIALS USED IN MANUFACTURE OF DEVICES USED IN BLOOD COLLECTION, CIRCULATION, STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-07-04 | — | — | US | disclosed |
| US-6350764-B2 | FOR INHIBITING LOSS OF BLOOD PLATELETS; INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, FIBRIN, THROMBUS, AND EMBOLUS; ANTICOAGULANTS EMBEDDED IN DEVICES FOR BLOOD COLLECTION, CIRCULATION, STORAGE (CATHETERS, DIALYSIS MACHINES); STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-26 | — | — | US | disclosed |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-01-17 | — | — | US | disclosed |
| US-6245763-B1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | CPT1A 4758/4885CPT2 4869/4885WDR5 1156/4885 |
| US-20030225115-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, F2R | CPT1A 4116/4885CPT2 4864/4885WDR5 2624/4885 |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | CPT1A 4041/4885CPT2 4854/4885WDR5 2770/4885 |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, PLAT | CPT1A 4097/4885CPT2 4861/4885WDR5 2719/4885 |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, F2R | CPT1A 4116/4885CPT2 4864/4885WDR5 2624/4885 |
| US-20040106633-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | CPT1A 4123/4885CPT2 4863/4885WDR5 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.